Le Lézard7h
Boehringer Canada Announces Availability of SPEVIGO® for expanded indication in Canada
Generalized pustular psoriasis (GPP) is a rare, chronic, heterogenous neutrophilic inflammatory disease associated with skin and systemic symptoms, such as fever, pain, and fatigue.1,2,3,4SPEVIGO's ...
National Institute for Health and Care Excellence22h
In consultation: Guidance and quality standards
Proposed changes to appeal period for technology appraisal and highly specialised technologies appeals Methods / process manual consultation NICE process and methods 16 February 2025 Spesolimab for ...
Fintel on MSN21h
Wolfe Research Initiates Coverage of AnaptysBio (ANAB) with Outperform Recommendation
Fintel reports that on February 4, 2025, Wolfe Research initiated coverage of AnaptysBio (NasdaqGS:ANAB) with a Outperform ...
Le Lézard7h
Enveda Expands into Asthma with First-in-Class Lead Asset ENV-294 and Assembles World-Class Advisory Board
Enveda, a biotechnology company using AI to translate nature into new medicines, is proud to announce testing of its lead asset, ENV-294, in a second indication: asthma. This novel therapeutic, ...
dermatologyadvisor5h
Drug Survival in Psoriasis Affected by Age at Initiation, Biologic Therapy Type
Age at initiation of treatment and the type of biologic therapy prescribed effect the rate of drug survival among patients with psoriasis.
AnaptysBio’s (ANAB) Outperform Rating Reiterated at Wedbush
AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “outperform” rating reaffirmed by equities researchers at Wedbush in a research note issued to investors on Monday,RTT News reports. They ...